Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis

Archives of Dermatology

Volumn 144, Issue 11, 2008, Pages 1527-1529

  Kreuter, Alexander ^a   Gambichler, Thilo ^b   Weiner, Stefan M ^b   Schieren, Gisela ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; CASE REPORT; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; KIDNEY FIBROSIS; LETTER; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; ULTRAVIOLET RADIATION;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; ULTRAVIOLET THERAPY;

EID: 56549084748     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.144.11.1527     Document Type: Letter

References (5)

1. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140(11):1322-1324.
2. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2):264-267.
3. Wahba IM, White K, Meyer M, Simpson EL. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy: report of two cases and review of the literature. Nephrol Dial Transplant. 2007;22(2):631-636.
4. Penfield JG, Reilly RF Jr. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3(12):654-668.
5. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143(8):1025-1030.